On Medicare? The $50 weight-loss pill program

Share
On Medicare? The $50 weight-loss pill program
CAPITALS INSIDERS
Markets, made simple — Evening edition · Thursday, November 5, 2026
Good evening. Today we covered oil this morning and Washington's borrowing at midday. Tonight, a story many readers will recognize from the pharmacy counter: a weight-loss pill that is selling far faster than expected, driven in large part by a Medicare program that caps the monthly cost at $50.
 
🌙 Evening Desk
A $50 Medicare price is turning a weight-loss pill into a hit
A pharmacist handing a prescription bag to a smiling older woman at a pharmacy counter
Start with the numbers. Novo Nordisk said its Wegovy pill, launched in January, brought in 5.39 billion Danish kroner, about $811 million, in the third quarter, up 53% from the prior quarter and well above analysts' estimates. Total company sales of about $11.9 billion also beat forecasts, and Novo raised its full-year outlook for the third time this year. Its shares rose about 6%.
The driver is Medicare. Under a pilot program called the GLP-1 Bridge, which began July 1 and runs through December 31, 2027, eligible Part D enrollees who use these drugs for weight management pay $50 a month out of pocket. Novo named the program as the main reason for the pill's growth. Because it runs outside the normal Part D system, the $50 does not count toward the Part D deductible or the annual out-of-pocket cap. It is a time-limited pilot, not a permanent change to Medicare coverage.
The weight-loss pill race, so far
Third-quarter sales
Wegovy pill sales, third quarter · billions of Danish kroner
Analyst consensus
Jefferies
 
4.96
Actual
about $811 million
 
5.39
Weight-loss pills, third-quarter sales · millions of dollars
Lilly's Foundayo
launched in April
 
$184M
Novo's Wegovy pill
launched in January
 
$811M
Sources: Novo Nordisk and Eli Lilly third-quarter results, as reported by BioPharma Dive and Tech Times, November 4.
The competition is close behind. Eli Lilly's own pill, Foundayo, launched in April and sold $184 million in the quarter, below estimates. Lilly still says it holds 63% of the U.S. market for this class of drugs when injections are included. The two pills differ in how they are taken: the Wegovy pill must be taken on an empty stomach 30 minutes before food or drink, while Foundayo has no meal restriction. No head-to-head trial comparing them has been completed.
For investors, Novo's report is a reminder of how much policy can move a business: the company's shares have lost about two-thirds of their value since mid-2024, and a single Medicare program is now helping to lift its forecasts. For readers on Medicare, the details matter more than the headlines. Eligibility depends on your Part D plan and your doctor, the $50 price is tied to a pilot with an end date, and these drugs carry side effects worth discussing with a physician.
 
📈 By the Numbers
Wegovy pill, Q3
About $811 million; up 53% from Q2.
Novo total sales
About $11.9 billion; outlook raised for the third time.
Medicare GLP-1 Bridge
$50 a month; July 1, 2026 to Dec. 31, 2027.
Lilly's Foundayo, Q3
$184 million, below estimates.
Still ahead
October jobs report Friday; Medicare open enrollment ends Dec. 7.
 
📜 Wisdom of the Street
“The art of medicine consists of amusing the patient while nature cures the disease.”
— Attributed to Voltaire
Today's medicine works faster than nature. Who pays for it, and for how long, is now a market story too.
 
Have a good evening.
— Lauren Miller, Capitals Insiders

Read more